On April 7, 2022 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern (Press release, Neoleukin Therapeutics, APR 7, 2022, View Source [SID1234611602]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast presentation can be accessed from the investors section of the Neoleukin website at View Source An archived replay will also be available on the company website for at least 30 days following the event.

On April 7, 2022 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference (Press release, Harpoon Therapeutics, APR 7, 2022, View Source [SID1234611601]). The discussion will take place on Thursday, April 14, 2022 at 2:30 p.m. ET (11:30 a.m. PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available in the Investors section of the Harpoon Therapeutics website at www.harpoontx.com with an archived replay available following the event.

On April 6, 2022 Cytokinetics, Incorporated (Nasdaq: CYTK) reported that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 11:00 AM ET (Presentation, Cytokinetics, APR 7, 2022, View Source [SID1234611599]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event.

On April 7, 2022 Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, reported that management will participate in two upcoming virtual investor conferences in April (Press release, Wugen, APR 7, 2022, View Source [SID1234611598]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

21st Annual Needham Virtual Healthcare Conference
Format: Panel titled "Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space"
Date/Time: Thursday, April 14, 2022 at 11:00 a.m. ET
Location: Virtual

Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Format: Fireside Chat
Date/Time: Tuesday, April 26, 2022 at 9 a.m. ET
Location: Virtual

On April 7, 2022 Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, reported that company leadership is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference, on Wednesday, April 13, 2022, at 3:00 p.m. EDT (Press release, Viracta Therapeutics, APR 7, 2022, View Source [SID1234611597]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at View Source The webcast will be archived for 30 days.